Search

Displaying results 2861 - 2870 of 10000 in total
  1. Drug

    Maralixibat

    go.drugbank.com/drugs/DB16226
    ApprovedInvestigational

    with Alagille syndrome:[L43547] it was granted marketing authorization in Europe on 13 December 2022. … [A239249] Maralixibat represents the first FDA-approved treatment for cholestatic pruritus in patients with Alagille syndrome. It was granted FDA approval on 29 September 2021.

  2. Drug

    STX-100

    go.drugbank.com/drugs/DB16334
    Investigational

    STX-100 is under investigation in clinical trial NCT01371305 (STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)).

  3. Drug

    NKG2D-ACE2 CAR-NK Cell

    go.drugbank.com/drugs/DB15727
    Investigational

    First used with autologous human T cells (CAR-T) as cancer immunotherapies, these receptors are now being engineered onto natural killer (NK) cells due to lower potential for graft-versus-host disease … The GM-CSF acts as a neutralizer for the CAR-T cell-mediated cytokine release and neurotoxicity.

  4. Drug

    Pipradrol

    go.drugbank.com/drugs/DB11584
    ApprovedWithdrawn

    In addition to this, it has shown favorable effects in postpartum depressive symptoms [L2516]. … The social and in particular acute clinical harms of pipradrol derivatives have led to their control under the Misuse of Drugs Act 1971 in the UK in 2012 [T178].

  5. Drug

    Streptococcus pneumoniae type 19a capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10337
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: Prevnar 20, PNEUMOVAX 23 0,5 ML ENJEKSIYONLUK COZELTI ICEREN FLAKON, 1 ADET
  6. Drug

    Tisotumab vedotin

    go.drugbank.com/drugs/DB16732
    ApprovedInvestigational

    [A238914] On September 20, 2021, the FDA granted accelerated approval to tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer in adults in whom the disease progressed during … The approval was based on tumour response and the durability of the response as demonstrated in InnovaTV 204 (NCT03438396): in this trial, the objective response rate was 24% and the median response duration

  7. Drug

    Profenamine

    go.drugbank.com/drugs/DB00392
    Approved

    It is primarily used as an antidyskinetic to treat Parkinsonism. It is sold under the trade name Parsitan in Canada.[L46812] In the US, the marketing of profenamine has been discontinued.[L46817]

    Synonyms: N,N-diethyl-1-(10H-phenothiazin-10-yl)-2-propanamine, N,N-diethyl-α-methyl-10H-phenothiazine-10-ethanamine
  8. Drug

    Celiprolol

    go.drugbank.com/drugs/DB04846
    ApprovedInvestigationalWithdrawn

    In 2010 a clinical trial has suggested a use for this medication in the prevention of vascular complications of a rare inherited disease called vascular Ehlers–Danlos syndrome. … Celiprolol is not approved for use by the FDA in the treatment of vascular Ehlers–Danlos syndrome.

    Synonyms: RS)-N'-{3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-N,N-diethylurea
  9. Drug

    Metaraminol

    go.drugbank.com/drugs/DB00610
    Approved

    It has been used primarily as a vasoconstrictor in the treatment of hypotension. … An adrenergic agonist that acts predominantly at alpha adrenergic receptors and also stimulates the release of norepinephrine.

    Synonyms: m-Hydroxypropadrine, m-Hydroxy norephedrine
  10. Drug

    Pegsunercept

    go.drugbank.com/drugs/DB06611
    Investigational

    Phase II clinical trials were completed in January 2010.

    Categories: Compounds used in a research, industrial, or household setting